Comment on Harvard Bioscience (HBIO), first successful transplant of a regenerated trachea by Catherine Tanner

Catherine Tanner — Fri, 17 May 2013 12:47:12 +0000

I found your article very interesting and began researching past surgeries involving synthetic tracheal scaffolds. What I’ve found is that HART simply provided the bioreactor, NOT the scaffold, although much of the press coming from HART leads one to believe they developed everything.

Who has been the primary developer of the tracheal scaffolds for surgeries involving the HART InBreath bioreactor?

Comment on RegMed Sector, humpty dumpty fell off the wall … where are all the King’s men to put him together again? by Rob Herrera

Rob Herrera — Wed, 03 Apr 2013 21:26:34 +0000

Clinical trial cancelled, half its workforce fired. Very hard to see
a recovery. From a balance sheet perspective, Q3-12, 21M Cash, Net Rev -6M,
Liabilities reduced to 6.99M. No intangible assets…

It is hard to believe that ASTM has been around since 1998, when it traded at 50s.
Granted, valuations on Regenerative Medicine Therapy companies are low and a potential opportunity. However, ASTM has shown no revenue, and with little cash and no trials, seems like a very rough spot.

IMO, even the pure-breed, high-burn therapeutic biotechs have
to show some cash flow through licensing, grants, services or tools. Balance sheet management through business model versatility. Too late to reinvent? I’ll leave that to the philosophers…

Comments for Scimitar Equity Blog

Comment on Harvard Bioscience (HBIO), first successful transplant of a regenerated trachea by Catherine Tanner

Comment on RegMed Sector, humpty dumpty fell off the wall … where are all the King’s men to put him together again? by Rob Herrera